Atara Biotherapeutics Inc (ATRA)
0.69
-0.01
(-1.40%)
USD |
NASDAQ |
Apr 26, 16:00
0.6911
0.00 (0.00%)
After-Hours: 20:00
Atara Biotherapeutics Revenue (Quarterly): 4.252M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 4.252M |
| September 30, 2023 | 2.138M |
| June 30, 2023 | 0.957M |
| March 31, 2023 | 1.226M |
| December 31, 2022 | 0.221M |
| September 30, 2022 | 4.459M |
| Date | Value |
|---|---|
| June 30, 2022 | 51.58M |
| March 31, 2022 | 7.314M |
| December 31, 2021 | 7.548M |
| September 30, 2021 | 5.37M |
| June 30, 2021 | 3.87M |
| March 31, 2021 | 3.552M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.221M
Minimum
Dec 2022
51.58M
Maximum
Jun 2022
7.707M
Average
4.061M
Median
Revenue (Quarterly) Benchmarks
| NovaBay Pharmaceuticals Inc | 3.727M |
| Palatin Technologies Inc | 2.034M |
| iBio Inc | -- |
| Theriva Biologics Inc | -- |
| Oragenics Inc | -- |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -60.45M |
| Total Expenses (Quarterly) | 64.21M |
| EPS Diluted (Quarterly) | -0.56 |
| Enterprise Value | 30.63M |
| Gross Profit Margin (Quarterly) | 25.68% |
| Profit Margin (Quarterly) | -1.42K% |
| Earnings Yield | -379.7% |
| Normalized Earnings Yield | -379.71 |